$9.08
1.68% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US88025U1097
Symbol
TXG
Sector
Industry

10x Genomics Inc - Ordinary Shares - Class A Stock price

$9.08
+1.40 18.23% 1M
-4.24 31.83% 6M
-5.28 36.77% YTD
-15.75 63.43% 1Y
-41.08 81.90% 3Y
-68.92 88.36% 5Y
-43.67 82.79% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.15 1.68%
ISIN
US88025U1097
Symbol
TXG
Sector
Industry

Key metrics

Market capitalization $1.13b
Enterprise Value $786.80m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 17.35
EV/Sales (TTM) EV/Sales 1.26
P/S ratio (TTM) P/S ratio 1.81
P/B ratio (TTM) P/B ratio 1.58
Revenue growth (TTM) Revenue growth -0.13%
Revenue (TTM) Revenue $624.66m
EBIT (operating result TTM) EBIT $-181.23m
Free Cash Flow (TTM) Free Cash Flow $45.36m
Cash position $426.91m
EPS (TTM) EPS $-1.30
P/E forward negative
P/S forward 1.92
EV/Sales forward 1.33
Short interest 21.36%
Show more

Is 10x Genomics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

10x Genomics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast:

8x Buy
40%
10x Hold
50%
2x Sell
10%

Analyst Opinions

20 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast:

Buy
40%
Hold
50%
Sell
10%

Financial data from 10x Genomics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
625 625
0% 0%
100%
- Direct Costs 183 183
26% 26%
29%
442 442
17% 17%
71%
- Selling and Administrative Expenses 321 321
7% 7%
51%
- Research and Development Expense 260 260
8% 8%
42%
-139 -139
16% 16%
-22%
- Depreciation and Amortization 42 42
10% 10%
7%
EBIT (Operating Income) EBIT -181 -181
14% 14%
-29%
Net Profit -157 -157
41% 41%
-25%

In millions USD.

Don't miss a Thing! We will send you all news about 10x Genomics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

10x Genomics Inc - Ordinary Shares - Class A Stock News

Neutral
PRNewsWire
6 days ago
PLEASANTON, Calif. , May 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has reached a settlement agreement with Bruker Corporation, successfully resolving all outstanding worldwide patent litigation and disputes between the two companies.
Neutral
Seeking Alpha
12 days ago
10x Genomics, Inc. (NASDAQ:TXG ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Cassie Corneau – Senior Director, Investor Relations Serge Saxonov – Chief Executive Officer and Co-Founder Adam Taich – Chief Financial Officer Conference Call Participants Patrick Donnelly – Citi Kyle Mikson – Canaccord Genuity Madeline Mollman – Wolfe Research Matt Sykes – Goldman Sa...
Neutral
PRNewsWire
12 days ago
PLEASANTON, Calif. , May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025.
More 10x Genomics Inc - Ordinary Shares - Class A News

Company Profile

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.

Head office United States
CEO Serge Saxonov
Employees 1,306
Founded 2012
Website www.10xgenomics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today